Navigation Links
FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
Date:10/29/2008

BRIDGEWATER, N.J., Oct. 29 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) approved Apidra(R) (insulin glulisine [rDNA origin] injection) to improve glycemic control in children (4 years and older) with diabetes mellitus.

The approval of Apidra(R) for pediatric use is based upon FDA review of a 26-week, phase III, open-label, active control study of Apidra(R) in comparison with insulin lispro, in 572 children and adolescents (4 years and older) with type 1 diabetes.

"Sanofi-aventis is committed to providing children with diabetes, as well as their families and healthcare providers, with safe and effective treatment options to help address the challenges associated with the condition and to help decrease the long-term risk for devastating complications of diabetes," said Michelle Baron, MD, vice president, Metabolism Medical Unit, sanofi-aventis U.S. "We are pleased that the fast onset of action and mealtime dosing flexibility of Apidra(R) will now be available to children 4 years and older."

Apidra(R) has a rapid onset and short duration of action and should normally be used in combination with a longer-acting or basal insulin. Apidra(R) can also be used in insulin infusion pump therapy for blood sugar control.

About the Study

The approval of Apidra(R) for pediatric use is based upon a 26-week, phase III, open-label, active control study of Apidra(R) in comparison with insulin lispro in 572 children and adolescents (4 - 17 years of age) with type 1 diabetes. Study patients received insulin glulisine or lispro 0-15 minutes premeal. These patients received concomitant treatment with insulin glargine once daily or NPH twice daily as basal insulin. The majority of the patients received insulin glargine as part of their basal-prandial regimen (69.7% and 72% in the Apidra(R) and insulin lispro treated groups, respectively).

The study compared the efficacy of Apidra(R
'/>"/>

SOURCE Sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014 EXECUTIVE ... Nutraceuticals Industry Outlook to 2017 - Increasing Demand ... comprehensive analysis of the industry past, present and ... Canada market with outlook ... and dietary supplements. Additionally the sub-segments of the ...
(Date:9/30/2014)... , September 30, 2014 ... Inc. (NASDAQ: IMMU ), Aeterna Zentaris Inc. ... OPK ), Navidea Biopharmaceuticals Inc. (NYSE MKT: ... on these five companies can be accessed at: ... the NASDAQ Composite ended at 4,505.85, down 0.14%, the ...
(Date:9/30/2014)... N.C. , Sept. 30, 2014 ... Viztek LLC (Viztek), a leading provider of complete ... HeartIT,s zero footprint patent portfolio. The licensed patents ... provide access to diagnostic-quality medical images in a ... of the agreement, Viztek and its Subsidiaries will ...
Breaking Medicine Technology:North America Nutraceuticals Industry Outlook to 2017- Increasing Demand from Ageing Population to Drive Growth 2North America Nutraceuticals Industry Outlook to 2017- Increasing Demand from Ageing Population to Drive Growth 3Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 2Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 3Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 4Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 5
... RALEIGH, N.C., June 7, 2011 BioDelivery Sciences International, ... Mark A. Sirgo, President and Chief Executive Officer of ... at the Grand Hyatt, New York City.  The presentation ... Eastern Time.   (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) ...
... Healthmark Industries was honored with two award wins ... Service Personnel (MSHCSP). At last week,s annual ... the Lifetime Honorary Achievement Award for his service to ... The same night Healthmark was also awarded the "Robert ...
Cached Medicine Technology:BioDelivery Sciences to Present at the Jeffries Global Healthcare Conference 2BioDelivery Sciences to Present at the Jeffries Global Healthcare Conference 3
(Date:9/30/2014)... and its partners successfully established a visual mapping ... myeloid derived suppressor cells (MDSC). The damage and ... understood, however this is a major stepping stone ... by tumor-derived factors from precursors present in hematopoietic ... spleen. This population of cells suppresses the activity ...
(Date:9/30/2014)... for a genetic condition would cut their risk of ... found. , In a major study, Dr Ian Frayling ... the University of Exeter,s Medical School assessed the effectiveness ... condition known as Lynch Syndrome. ... genes which check the spelling in DNA. The condition ...
(Date:9/30/2014)... people who are diagnosed with bowel cancer would be ... them and their relatives, new research has concluded. ... were funded by the National Institute for Health Research ... effectiveness and cost-effectiveness of screening for Lynch Syndrome. Their ... that screening the 1,700 people under the age of ...
(Date:9/30/2014)... 2014 This two-day, advanced PT ... sequellae that may arise following a concussion or ... can be varied, from sports related injuries, car accidents, ... by the thousands of returning soldiers from war zone ... and blunt traumas can result in similar injuries, the ...
(Date:9/30/2014)... HealthDay Reporter , MONDAY, ... given broad-spectrum antibiotics before the age of 2 may ... childhood, new research suggests. Broad-spectrum antibiotics target a ... the study. "It is a reason to think ... are picking," said lead researcher Dr. Charles Bailey, attending ...
Breaking Medicine News(10 mins):Health News:Genetic test would help 'cut bowel cancer spread' 2Health News:Genetic test would help 'cut bowel cancer spread' 3Health News:Genetic test for cancer patients could be cost-effective and prevent further cases 2Health News:Genetic test for cancer patients could be cost-effective and prevent further cases 3Health News:North American Seminars Presents Traumatic Brain Injury and Concussions in Conduction with St. Anthony's Medical Center in St. Louis, MO on November 8-9, 2014 2Health News:North American Seminars Presents Traumatic Brain Injury and Concussions in Conduction with St. Anthony's Medical Center in St. Louis, MO on November 8-9, 2014 3Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 2Health News:Antibiotic Use Before Age 2 Might Raise Obesity Risk, Study Says 3
... BEACH, Calif., May 1 With the world gripped by ... epidemic, how can people be adequately prepared for the dangers ... Newport Beach psychologist, says, "People need to be informed, prepared, ... in this moment." People are obsessing over the swine ...
... HULL, England, May 1 Smith & Nephew,s Advanced Wound Management ... Patents Court, in the High Court of Justice of England and ... asserted against Smith & Nephew of the Negative Pressure Wound Therapy ... (KCI) (NYSE: KCI ). The 3 other claims ...
... The Quigley Corporation, (Nasdaq: QGLY ) ... of $4.0 million, for the first quarter ended March 31, 2009, ... decrease in net sales for the first quarter of 2009 reflects ... reported by Information Resources Inc., ("IRI") data, general economic weakness and ...
... 1 Gaiam, Inc. (Nasdaq: GAIA ), ... products and services to customers who value personal development, ... announce results for the first quarter ended March 31, ... 6, 2009. The Company will hold a teleconference to ...
... to $2.70 - $2.85 per Diluted ShareVIRGINIA BEACH, Va., May 1, ... that its net income for the first quarter of 2009 increased ... income of $33.6 million, or $0.62 per diluted share, for the ... , ...
... fitness, and performance services, recently supported Global Medical Brigades on a ... ... Brook, IL (PRWeb) May 1, 2009-- AthletiCo , an Illinois-based ... Medical Brigades on a medical mission trip to Honduras. ...
Cached Medicine News:Health News:How to Be Prepared for, but Not Paralyzed by Fear of, the Swine Flu Epidemic 2Health News:Smith & Nephew Encouraged by United Kingdom NPWT Patent Court Decision 2Health News:Smith & Nephew Encouraged by United Kingdom NPWT Patent Court Decision 3Health News:The Quigley Corporation Reports First Quarter 2009 Results 2Health News:The Quigley Corporation Reports First Quarter 2009 Results 3Health News:The Quigley Corporation Reports First Quarter 2009 Results 4Health News:The Quigley Corporation Reports First Quarter 2009 Results 5Health News:The Quigley Corporation Reports First Quarter 2009 Results 6Health News:The Quigley Corporation Reports First Quarter 2009 Results 7Health News:The Quigley Corporation Reports First Quarter 2009 Results 8Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 2Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 3Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 4Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 5Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 6Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 7Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 8Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 9Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 10Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 11Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 12Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 13Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 14Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 15Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 16Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 17Health News:AMERIGROUP Reports Q1 Net Income of $36.9 Million or $0.69 per Diluted Share 18Health News:AthletiCo Employees Volunteer Time And Talent To Support Global Medical Brigades 2Health News:AthletiCo Employees Volunteer Time And Talent To Support Global Medical Brigades 3
... Unparalleled Comfort Pick one of our pipettors ... the trigger and ejector positionsright where they should ... are ergonomically designed to help avoid repetitive stress ... Productivity In The Palm Of Your Hand ...
... for Unparalleled Comfort Pick one of our ... Notice the trigger and ejector positionsright where they ... pipettors are ergonomically designed to help avoid repetitive ... Productivity In The Palm Of Your Hand ...
... Ergonomic Design for Unparalleled Comfort Pick ... Notice the balance. Notice the trigger and ejector ... Thats because our pipettors are ergonomically designed to ... hours of pipetting. Productivity In The Palm ...
... The total ergonomic solution and best value ... feather touch action and ultra lightweight design ... tip ejection with long, lever tip ejector ... , Accepts universal tips or for greater ...
Medicine Products: